2019
Double‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use
Carroll KM, DeVito EE, Yip SW, Nich C, Sofuoglu M. Double‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use. American Journal On Addictions 2019, 28: 238-245. PMID: 31165574, PMCID: PMC9078084, DOI: 10.1111/ajad.12904.Peer-Reviewed Original ResearchConceptsMethadone-maintained individualsOpioid useSecondary analysisMultiple drugsConcurrent cocaine dependenceTrial of galantaminePlacebo-controlled trialDouble-blind placeboIllicit opioid useRandomized clinical trialsCocaine use disorderGalantamine's effectFuture trialsClinical trialsUrine specimenUrine specimensUse disordersOpioidsCholinesterase inhibitorsMaintenance settingCocaine useCocaine dependencePlaceboConcurrent useGalantamine
2018
Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder
Carroll KM, Nich C, Frankforter TL, Yip SW, Kiluk BD, DeVito EE, Sofuoglu M. Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder. Drug And Alcohol Dependence 2018, 192: 264-270. PMID: 30300800, PMCID: PMC6203294, DOI: 10.1016/j.drugalcdep.2018.08.019.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAnhedoniaAnxietyDepressionFemaleHumansMaleNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPatient DropoutsTreatment OutcomeConceptsOpioid use disorderOral naltrexoneUse disordersAffective symptomsVoucher-based contingency managementDysphoric symptomsAffective distressOral naltrexone treatmentMultiple baseline characteristicsBaseline characteristicsNaltrexone treatmentHigh riskNaltrexoneSomatic symptomsSymptomsContingency managementTreatmentHigh rateDistressSubstantial evidenceTrialsTheoretical benefitsDisordersAffective discomfortParticipantsCan neuroimaging help combat the opioid epidemic? A systematic review of clinical and pharmacological challenge fMRI studies with recommendations for future research
Moningka H, Lichenstein S, Worhunsky PD, DeVito EE, Scheinost D, Yip SW. Can neuroimaging help combat the opioid epidemic? A systematic review of clinical and pharmacological challenge fMRI studies with recommendations for future research. Neuropsychopharmacology 2018, 44: 259-273. PMID: 30283002, PMCID: PMC6300537, DOI: 10.1038/s41386-018-0232-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsBrainHumansMagnetic Resonance ImagingNeuroimagingOpioid-Related DisordersResearch DesignConceptsOpioid use disorderOpioid epidemicTreatment responseTask-based fMRI paradigmsUrgent public health problemMedication-assisted treatmentPrescription opioid usersCurrent opioid epidemicPublic health problemEvidence-based treatmentsPaucity of literatureHeroin cuesOpioid medicationsRelapse rateOpioid systemOpioid usersFuture neuroimaging studiesSignificant individual variabilityHealthcare costsWithdrawal effectsHealthy individualsHealth problemsSystematic reviewExtended abstinenceNeuroimaging studiesThe Cholinergic System as a Treatment Target for Opioid Use Disorder
Jensen KP, DeVito EE, Yip S, Carroll KM, Sofuoglu M. The Cholinergic System as a Treatment Target for Opioid Use Disorder. CNS Drugs 2018, 32: 981-996. PMID: 30259415, PMCID: PMC6314885, DOI: 10.1007/s40263-018-0572-y.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcholineAnalgesics, OpioidAnimalsCholinergic AgentsHumansNon-Neuronal Cholinergic SystemOpioid-Related DisordersConceptsCholinergic systemUse disordersTreatment targetsOpioid use disorder epidemicCentral nervous system functionTreatment of OUDEffects of acetylcholineOpioid use disorderTobacco use disorderNervous system functionOpioid medicationsDegrade acetylcholineCurrent treatmentOpioid overdosesPreclinical studiesMedicationsAcetylcholineCholinesterase inhibitorsAlzheimer's diseaseNew treatmentsAccidental deathGlobal healthTreatmentOUDDisease
2013
Gender differences in a clinical trial for prescription opioid dependence
McHugh RK, DeVito EE, Dodd D, Carroll KM, Potter JS, Greenfield SF, Connery HS, Weiss RD. Gender differences in a clinical trial for prescription opioid dependence. Journal Of Substance Use And Addiction Treatment 2013, 45: 38-43. PMID: 23313145, PMCID: PMC3626739, DOI: 10.1016/j.jsat.2012.12.007.Peer-Reviewed Original ResearchConceptsPrescription opioid dependenceOpioid dependenceClinical trialsOpioid dependence severityPrescription drug dependenceLarge clinical trialsOpioid use outcomesGreater functional impairmentRoute of administrationSubstance use disordersGender differencesGreater psychiatric severityClinical characteristicsMedication doseStudy treatmentOpioid outcomesFunctional impairmentTreatment outcomesPre-treatment differencesPsychiatric severityTreatment retentionUse disordersLegitimate prescriptionDrug dependenceOpioids